科济药业与Dispatch Bio Therapeutics近日共同宣布，双方已签署临床合作协议，将重点评估基于Dispatch Bio专有Flare技术平台开发的Zevor-Cel（CT041）在实体瘤治疗领域的潜力。这项合作旨在探索该创新CAR-T疗法针对多种实体瘤的临床效果与安全性。
通过整合科济药业在CAR-T细胞治疗领域的研发实力与Dispatch Bio的Flare平台技术，双方期望加速Zevor-Cel的临床开发进程。Flare平台以其高效靶向递送机制著称，有望提升CAR-T疗法在实体瘤微环境中的渗透性与持久性。Zevor-Cel作为靶向Claudin18.2的CAR-T产品，此前已在胃癌、胰腺癌等实体瘤中展现出初步疗效。
此次合作将聚焦于临床前研究及早期临床试验设计，为后续扩大适应症范围奠定基础。双方未披露具体财务条款及开发时间表，但表示将共享实验数据与研发资源，共同推进实体瘤免疫治疗的创新突破。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.